ЎПКАНИНГ СУРУНКАЛИ ОБСТРУКТИВ КАСАЛЛИКЛАРИ БОР БЕМОРЛАРДА COVID-19 БИЛАН ОҒРИГАНДА СИНУСИТЛАРНИНГ КЛИНИК КАРТИНАСИ
##article.subject##:
синусит, covid – 19 дан кейинги холат, упканинг сурункали обструктив касаллиги, резонанс терапия, хаёт сифати, кон томир микроциркуляцияси##article.abstract##
Коронавирус инфекциясидан кейин юқори жағ ва бронхларнинг ўзаро патологиясининг аҳамияти нафақат касалликларнинг тарқалиши ва оғирлигига, умуман танага салбий таъсир кўрсатиши, балки даволанишнинг паст самарадорлиги билан ҳам белгиланади. Коронавирус инфекциясидан кейинги терапевтик чора-тадбирларнинг асосий йўналишларидан бири бундай беморларда аниқланган гемостатик тизимнинг мувозанатини тузатишдир (Орехова Л.Ю.ҳам муаллиф., 2020; Шапавалов В.Д., 2020). Маҳаллий ва хорижий адабиётларда, бошқа мутахассис шифокорлар билан стоматологлар биргаликда олиб борилган, сурункали обструктив ўпка касаллиги ва бронхиал астма билан бирга cовид – 19 (ҲC - ПC), кейин сурункали синусит даволаш тизимли усуллари комплекс ёндашув имкониятлари ҳақида илмий асосланган маълумотлар деярли йўқ.
Библиографические ссылки
Alyavi AL, Rakhimova DA, Sadykova GA Clinical and functional state in patients with chronic obstructive pulmonary disease at different degrees of pulmonary heart severity. III Congress of Thoracic Society of Kyrgyzstan.Bishkek, 2011: 83.
Alyavi A.L., Rakhimova D.A., Sadykova G.A. Clinical and experimental aspects of ozone therapy. Uzbekistan therapy ahborot-nomasi. Tashkent, 2015; 4: 74-78.
Baevsky R.M., Ivanov G.G. To the question of formalization of conclusions on the results of analysis of psychological approach to HRV. // Functional diagnostics. 2016. №2. 89-94
Chuchalin A.G. Chronic obstructive pulmonary disease and associated diseases. М.-2018. 25p.
Global initiative for chronic obstructive ling disease. Global strategy for the diagnosis, management and prevention of chronic obstruktive pulmonary disease. NHLBI / WHO workshop report. Bethesda: National Heart, Lung and Blood institute: update 2016 (W Wgoldcopd. com).
Calverley P.M., Walker P. Chronic obstructive pulmonary disease. //Lancet.-2016.-vol.362.-p.1053-1061.
Peiffer,C.J., B. Poline, L. Thivard, M. Aubier, Y. Samson. Neural substrates for the perception of acutely induced dyspnea. Am J Respir Crit Care Med. 2016.163(4):951–72
Rakhimova D.A., Kasimova, G.M. Estimating psychovegetative factors of regulation in patients with chronic obstructive pulmonale diseases. «Journal of life-sciences». Argentina, 2012; 4: 457-461.
Broekhuizen R, Wouters EF, Creutzberg EC, Schols AM. Raised CRP levels to mark metabolic and functional impairment in advanced COPD // Thorax. -2006. -Vol.61. - P.17-22.
Burgel PR, Paillasseur JL, Peene B, et al. Two distinct chronic obstructive pulmonary diseases (COPD) phenotypes are associated with a high risk of mortality // PLoS One. -2012. -Vol.7. - P.e51048.
Celli B.R., Macnee W. Сommittee members. standarts for diagnosing and treating patients with COPD: a summary of the ATS / ERS-Position paper // Eur. Respuir. J. -2004. -Vol. 23(6). - P.932-946.
Obstructive pulmonary disease, Saskatchewan Canada cardiovascular disease in COPD patients // Ann. Epidemiol. -2006.-Vol.16. -P.63-70.
Hurd S. S., Lenfant C. COPD: good lung health is the key. Comment // Lancet.- 2005.- V.366. -P.1832–1834.
Mannino D.M., Buist A.S. Global burden of COPD: risk factors, prevalence, and future trends // Lancert. -2007. -Vol.370. -P.765-773.
Metabolic syndrome and its effects in COPD patients/ Memis U., Sagcan G., Engin R. et al.// The Toraks Dergisi: Abst.Turkish Thoracic Society.- 2009.-MS024.-162s.
Report GOLD: Global initiative for chronic obstructive lung disease, update 2008, available on www.goldcopd.org
